Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biosafe Medical Technologies has announced the development of the first consumer test to evaluate diabetes risk. The diabetes risk assessment test will be marketed exclusively in the US by Glycemion.
Subscribe to our email newsletter
The Biosafe diabetes risk assessment is a two-part process comprised of an immediate fasting glucose reading and a mail-in laboratory analysis for hemoglobin A1c, a blood glucose marker for the previous ninety-day period. Samples for both tests can be either professionally collected or self-collected through the use of a simple finger-nick collection kit. Taken in combination, these two results are said to become a reliable indicator of diabetes or a pre-diabetes condition.
Jack Maggiore, president of Biosafe Laboratories, said: “The Biosafe diabetes risk assessment is a common-sense approach to early detection of a potentially dangerous condition.”